-
EP1218015
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1218015
| EP1218015 - PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETIC AGENT [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 26.03.2004 Database last updated on 19.10.2024 | Most recent event Tooltip | 26.03.2004 | Application deemed to be withdrawn | published on 12.05.2004 [2004/20] | Applicant(s) | For:BE
CH
CY
DE
DK
ES
FI
FR
GB
GR
IE
IT
LU
MC
NL
PT
SE
LI
Novartis AG Lichtstrasse 35 4056 Basel / CH | For:AT
Novartis Pharma GmbH Brunner Strasse 59 1230 Wien / AT | [N/P] |
| Former [2003/11] | For:BE
CH
CY
DE
DK
ES
FI
FR
GB
GR
IE
IT
LU
MC
NL
PT
SE
LI
Novartis AG Lichtstrasse 35 4056 Basel / CH | ||
| For:AT
Novartis Pharma GmbH Brunner Strasse 59 1230 Wien / AT | |||
| Former [2003/10] | For:BE
CH
CY
DE
DK
ES
FI
FR
GB
GR
IE
IT
LU
MC
NL
PT
SE
LI
Novartis AG Lichtstrasse 35 4056 Basel / CH | ||
| For:AT
Novartis Pharma GmbH Brunner Strasse 59 1235 Vienna / AT | |||
| Former [2002/27] | For:BE
CH
CY
DE
DK
ES
FI
FR
GB
GR
IE
IT
LU
MC
NL
PT
SE
LI
Novartis AG Lichtstrasse 35 4056 Basel / CH | ||
| For:AT
Novartis-Erfindungen Verwaltungsgesellschaft m.b.H. Brunner Strasse 59 1235 Wien / AT | Inventor(s) | 01 /
GATLIN, Marjorie, Regan 913 Lovering Avenue Wilmington, DE 19806 / US | 02 /
BALL, Michele 9 Shady lane Kendall Park, NJ 08824 / US | 03 /
DUNNING, Beth 263 Bradley Street Battle Creek, MI 49017 / US | [2002/27] | Representative(s) | Grubb, Philip William, et al Novartis AG Corporate Intellectual Property Lichtstrasse 35 4002 Basel / CH | [N/P] |
| Former [2003/20] | Grubb, Philip William, et al Novartis AG, Corporate Intellectual Property, Lichtstrasse 35 4002 Basel / CH | ||
| Former [2002/27] | Becker, Konrad, et al Novartis AG, Corporate Intellectual Property, Patent & Trademark Department 4002 Basel / CH | Application number, filing date | 00972695.1 | 06.10.2000 | [2002/27] | WO2000EP09816 | Priority number, date | US19990415307 | 08.10.1999 Original published format: US 415307 | US19990415308 | 08.10.1999 Original published format: US 415308 | [2002/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO0126639 | Date: | 19.04.2001 | Language: | EN | [2001/16] | Type: | A2 Application without search report | No.: | EP1218015 | Date: | 03.07.2002 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.04.2001 takes the place of the publication of the European patent application. | [2002/27] | Search report(s) | International search report - published on: | EP | 10.01.2002 | Classification | IPC: | A61K31/70, A61K31/445, A61K31/195, A61P3/00 | [2002/27] | CPC: |
A61K31/195 (EP);
A61K31/445 (EP);
A61K31/702 (EP);
A61K31/715 (EP);
A61K45/06 (EP);
A61P3/00 (EP)
| C-Set: |
A61K31/445, A61K2300/00 (EP);
A61K31/445, A61K31/195 (EP);
A61K31/702, A61K2300/00 (EP);
A61K31/702, A61K31/195 (EP); | Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2002/27] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | RO | 28.02.2002 | SI | 28.02.2002 | Title | German: | ZUSAMMENSETZUNG WELCHE NATEGLINIDE AND EINE ANDERE ANTIDIABETISCHE VERBINDUNG ENTHÄLT | [2002/27] | English: | PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETIC AGENT | [2002/27] | French: | PROCEDE DE TRAITEMENT DE TROUBLES DU METABOLISME | [2002/27] | Entry into regional phase | 28.02.2002 | National basic fee paid | 28.02.2002 | Designation fee(s) paid | 28.02.2002 | Examination fee paid | Examination procedure | 09.04.2001 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 28.02.2002 | Examination requested [2002/27] | 25.06.2003 | Despatch of a communication from the examining division (Time limit: M04) | 10.12.2003 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2004/20] | 05.01.2004 | Application deemed to be withdrawn, date of legal effect [2004/20] | Fees paid | Renewal fee | 31.10.2002 | Renewal fee patent year 03 | 31.10.2003 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]EP0749751 (TAKEDA CHEMICAL INDUSTRIES LTD [JP]) [X] 1-3,5,7-13 * page 9, line 41 - line 51 * * page 8, line 34 - line 40 *; | [X] - PERFETTI R ET AL, "NOVEL THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES", DIABETES/METABOLISM REVIEWS,US,WILEY, NEW YORK, NY, (1998), vol. 14, no. 3, ISSN 0742-4221, pages 207 - 225, XP000908775 [X] 1-3,5,7-13 * page 211, column 1, paragraph 5 - column 2, paragraph 3 * * page 213, column 2, paragraph 3 - page 214, paragraph 2 * * page 220, column 2, paragraph 2 * DOI: http://dx.doi.org/10.1002/(SICI)1099-0895(1998090)14:3<207::AID-DMR214>3.0.CO;2-J | [A] - BLOOMGARDEN Z.T., "American diabetes association annual meeting, 1998: More on the treatment of type 2 diabetes.", DIABETES CARE, 22/2 (357-361)., (199902), XP000997498 [A] 1-13 * page 358, column 1 - column 2, paragraph 1 * * page 359, column 3, paragraph 2 - page 360, column 1, paragraph 1 * | [A] - DUNNING B.E., "Nateglinide: A glucose-sensitive insulinotropic agent that is chemically and pharmacologically distinct from the sulfonylureas.", CURRENT OPINION IN ENDOCRINOLOGY AND DIABETES, (1999) 6/SUPPL. 1 (S29-S31)., XP000997507 [A] 1-13 * abstract * |